Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02261805 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02261805 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 11 participants.
The verdict
NCT02261805, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a Phase I/safety dose expansion study of the combination of the drug ganetespib and doxorubicin in patients with advanced solid tumors. The purpose of the Phase I part of the study is to determine the recommended phase II dose of ganetespib when given in combination with doxorubicin. The recommended Phase II dose determined at the end of the dose escalation phase will be used to conduct a safety dose expansion phase in relapsed/refractory small cell lung cancer to determine if there is a signal of efficacy in this population.
Interventions
- DRUG Doxorubicin
- DRUG Ganetespib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02261805
The ClinicalTrials.gov registry entry for NCT02261805 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT02261805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02261805 about?
NCT02261805 is a clinical study titled "A Phase I/II Study of Ganetespib in Combination With Doxorubicin". This is a Phase I/safety dose expansion study of the combination of the drug ganetespib and doxorubicin in patients with advanced solid tumors. The purpose of the Phase I part of the study is to determine the recommended phase II dose of ganetespib when given in combination with doxorubicin. The rec...
What is the current status of trial NCT02261805?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2014-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02261805?
The interventions under investigation include: Doxorubicin (DRUG), Ganetespib (DRUG).
Who is sponsoring clinical trial NCT02261805?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.